Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
C4 Therapeutics, Inc.
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
April 28, 2026
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
←
Previous Page
1
2